Last reviewed · How we verify
Mailed nicotine replacement therapy
Mailed nicotine replacement therapy is a Nicotine replacement therapy Small molecule drug developed by Massachusetts General Hospital. It is currently FDA-approved for Smoking cessation, Reduction of tobacco withdrawal symptoms.
Nicotine replacement therapy delivered by mail provides nicotine to reduce withdrawal symptoms and cravings during smoking cessation.
Nicotine replacement therapy delivered by mail provides nicotine to reduce withdrawal symptoms and cravings during smoking cessation. Used for Smoking cessation, Reduction of tobacco withdrawal symptoms.
At a glance
| Generic name | Mailed nicotine replacement therapy |
|---|---|
| Sponsor | Massachusetts General Hospital |
| Drug class | Nicotine replacement therapy |
| Target | Nicotinic acetylcholine receptors |
| Modality | Small molecule |
| Therapeutic area | Smoking Cessation / Addiction Medicine |
| Phase | FDA-approved |
Mechanism of action
Nicotine binds to nicotinic acetylcholine receptors in the central nervous system, mimicking the effects of smoked nicotine and reducing the physical and psychological symptoms of tobacco withdrawal. By delivering nicotine through a non-combustible route (patches, gum, lozenges, or nasal spray), it allows patients to gradually reduce their dependence on cigarettes while managing withdrawal symptoms. The mail-based delivery model improves accessibility and adherence to nicotine replacement therapy.
Approved indications
- Smoking cessation
- Reduction of tobacco withdrawal symptoms
Common side effects
- Nausea
- Dizziness
- Headache
- Insomnia
- Irritability
- Local skin irritation (patch formulation)
Key clinical trials
- Remote Interventions for Menthol Cigarette Use (NA)
- A Pragmatic Trial of Chronic Disease Approaches to Ameliorate Tobacco Related Cardiovascular Disease Health Disparities (NA)
- Implementing Tobacco Treatment in Low Dose CT Lung Cancer Screening Sites (PHASE4)
- Empowering Cessation ACS South Region (PHASE1, PHASE2)
- Developing Empowering Smoking Cessation (EARLY_PHASE1)
- Perioperative Smoking Cessation BUndle in a Tertiary Care Hospital - Can Turning Virtual Improve Outcomes? (NA)
- New Strategies to Enhance Smoking Cessation (NA)
- BREATHE 2 Clinic Stop-Smoking Treatment Outreach Study (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Mailed nicotine replacement therapy CI brief — competitive landscape report
- Mailed nicotine replacement therapy updates RSS · CI watch RSS
- Massachusetts General Hospital portfolio CI
Frequently asked questions about Mailed nicotine replacement therapy
What is Mailed nicotine replacement therapy?
How does Mailed nicotine replacement therapy work?
What is Mailed nicotine replacement therapy used for?
Who makes Mailed nicotine replacement therapy?
What drug class is Mailed nicotine replacement therapy in?
What development phase is Mailed nicotine replacement therapy in?
What are the side effects of Mailed nicotine replacement therapy?
What does Mailed nicotine replacement therapy target?
Related
- Drug class: All Nicotine replacement therapy drugs
- Target: All drugs targeting Nicotinic acetylcholine receptors
- Manufacturer: Massachusetts General Hospital — full pipeline
- Therapeutic area: All drugs in Smoking Cessation / Addiction Medicine
- Indication: Drugs for Smoking cessation
- Indication: Drugs for Reduction of tobacco withdrawal symptoms
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing